Morgan Stanley has restarted coverage of Accor SA with an "equal-weight" recommendation and a price target of €51, arguing that the hotel operators recently announced sale of its stake in Essendi for €975 million largely completes its move toward an asset-light structure but leaves the investment case evenly balanced.
The brokerages €51 target implies about 10% upside from Accors July 24 closing share price of €46.31. Morgan Stanley also published scenario analysis showing a €70 bull case, representing roughly a 52% potential gain, and a €35 bear case, equivalent to about a 25% decline.
While the broker acknowledges potential upside from narrowing the valuation gap with peers, it says several constraints make that outcome unlikely in the near term. These include what Morgan Stanley describes as the ongoing Middle East situation weighing on revenue per available room - RevPAR - net unit growth that remains below peers, a weak first half, and lingering uncertainty around Accors fee algorithm. The firm therefore advised investors to await a more attractive entry point and maintained its Equal-weight stance.
Following the Essendi transaction, Morgan Stanley notes Accors Managed & Franchised division now contributes roughly 80% of group EBITDA, operating at a 66% margin with about 90% unlevered free cash flow conversion. The firm also highlighted that Accor plans to return €1 billion to shareholders over the next 12 months, equal to approximately 10% of market capitalisation, which would keep the company on track to exceed its €3 billion cash return target for 2023-27.
On valuation, Morgan Stanley calculates Accor is trading at 16 times price-to-earnings and 11 times EV/EBITDA on 2027 estimates, which the bank says is around a 25% discount to asset-light peers.
The report lists a set of company-specific operating characteristics and market exposures that temper upside potential. Accor carries a higher degree of operating leverage than many peers, with about 20% of EBITDA still coming from leases and the SMDL segment, and roughly one-third of Managed & Franchised revenue derived from incentive fees. The group's exposure to the Middle East stands at about 10% of sales, around twice the level of global peers, and RevPAR is no longer outperforming the market, with second-quarter RevPAR estimated to be flat according to Morgan Stanley.
Net unit expansion is another area of concern. Morgan Stanley cites net unit growth in the 3.5%-4% range, which it views as lagging most global competitors, particularly in the Premium, Midscale & Economy segments and within Europe.
The brokerage lays out its near-term financial expectations ahead of Accors July 30 results. Morgan Stanley forecasts first-half RevPAR growth of 2.6%, net unit growth of 3.6%, Managed & Franchised revenue of €697 million, and group EBITDA of €558 million, a 1.2% rise. Adjusted earnings per share are modelled at €1.02, up 5.7% year-on-year.
Looking to full-year 2026, Morgan Stanley anticipates Accor will guide to EBITDA of between €1.25 billion and €1.28 billion, equivalent to 7%-9% constant-currency growth. The bank observes that achieving consensus would require second-half EBITDA growth to accelerate to 9%-10%.
On the Essendi deal specifics, Accor has entered a binding agreement to sell its 30.7% stake in Essendi for €975 million to a consortium comprising Blackstone and Colony. Completion timing has been pushed from the third to the fourth quarter. The consideration structure includes €675 million payable on closing and an additional earn-out of up to €300 million.
Morgan Stanley estimates that this transaction, together with a related €500 million share buyback, will be roughly 2% accretive to full-year 2028 earnings per share.
Given the mix of positive structural change toward an asset-light model and the near-term operational and regional risks outlined above, Morgan Stanleys recommendation is cautious. The firm resumed coverage at Equal-weight and indicated it would prefer a more compelling valuation entry point before upgrading its stance.